MB2 Dental and Your Practice: What Owners Should Know in 2026
Most approaches ask you to sell your practice. This one asks you to buy into something.
That sounds like marketing. Then you look at how the deal is actually built, and it turns out to be the whole thing.
MB2 Dental calls itself a dental partnership organization rather than a DSO. The distinction is not cosmetic.
Affiliating dentists co-invest and hold equity rather than simply cashing out.
Whether that is better or worse for you depends entirely on what you want the next ten years to look like. Here is what it actually is.
Key takeaways
- MB2 is a DPO, not a conventional DSO. Affiliating dentists co-invest and retain equity, which changes both the economics and the risk profile.
- It is genuinely, actively acquisitive. In January 2026 alone it partnered with 11 practices across five states and added seven new doctor partners.
- Backed by Warburg Pincus and Charlesbank, with roughly 800 offices and affiliated practices across more than 45 states.
- Equity is the point, so evaluate the equity. Where it sits and what ranks above it decide whether the model works for you.
- The mid-market platforms are the most acquisitive buyers in dentistry, not the household names. That matters for who you should be talking to.
Does MB2 Dental buy dental practices? Yes, and actively. MB2 operates a doctor-partnership model in which affiliating dentists co-invest and retain equity rather than fully exiting.
In January 2026 it partnered with 11 practices across five states and welcomed seven new doctor partners.
Who MB2 Dental actually is
Founded in 2007. MB2 supports affiliated practices across more than 45 states, with roughly 800 offices.
Its private equity backing comes from Warburg Pincus and Charlesbank Capital Partners.
The structural label matters here. A DSO is a dental support organization: the management company owns the non-clinical side of a practice and handles everything outside the operatory, while a licensed dentist retains ownership of the clinical entity.
A DPO, a dental partnership organization, keeps the selling doctor as a meaningful owner rather than an employee, and usually preserves the local practice name rather than converting it to a house brand.
MB2 describes itself in the second category. Affiliating dentists co-invest alongside the organization and hold equity in the wider group.
Does MB2 buy practices, or build new ones?
Actively buys. At pace.
January 2026 alone: partnerships with 11 practices across five states, and seven new doctor partners joining. Its most recent recorded transaction at the time of writing was a buyout of Mancini Orthodontics on 9 January 2026.
That sits inside a broader pattern worth understanding.
Industry analysis of the buyer pool points at the 200-to-500-office mid-market platforms. MB2 sits in that band, alongside Smile Brands, Mortenson Dental Partners and Dental Care Alliance.
They are the most acquisitive buyers in dentistry on a per-platform basis, completing somewhere between 30 and more than 100 affiliations per year each.
Read that again if you have been assuming the biggest names are your most likely buyers. The organizations doing the most deals are not the ones with the largest advertising budgets.
And of the three largest DSOs in the country, only Heartland Dental is substantially acquisition-led; Aspen Dental and PDS Health grow primarily by opening new offices.
What the partnership model actually changes
This is where MB2 differs from a conventional sale, and where you need to think hardest.
In a straightforward acquisition, you take cash, you stay on for an agreed clinical period, and your financial relationship with the practice ends. Your outcome is fixed at closing.
In a co-investment model, part of your consideration is rollover equity, meaning a slice of ownership in the buyer’s company instead of all cash at close. Your eventual outcome depends on how the wider organization performs, not just on how your practice performs.
That cuts both ways. Honest advice acknowledges both.
The upside is a second payout. If the organization grows and recapitalizes at a higher valuation than when you joined, your rolled equity appreciates.
Owners who affiliated early with organizations that subsequently grew well have done very well from exactly this mechanism. It is often described as a second bite, and it is real.
The risk is that you have exchanged a liquid asset you controlled for an illiquid minority position in something you do not control. Your practice could perform beautifully while the return on your equity is set by decisions made elsewhere, in markets you have never visited, by people you did not hire.
Neither of those is a criticism of MB2. It is the arithmetic of the structure.
It applies to any co-investment model.
The questions the equity actually turns on
If equity is a meaningful part of what you are being offered, these are the questions that decide whether it is worth anything.
Where does the equity sit? Ownership in your own practice entity behaves very differently from ownership in the parent company. The first tends to have a higher floor and a lower ceiling, tracking a business you still influence.
The second rises and falls with a portfolio you do not.
What ranks above it? Liquidation preferences determine who gets paid first when the company is sold. Equity sitting underneath a stack of preferences can be worth considerably less than its stated value, and in a poor outcome can be worth very little.
When is liquidity expected? Rolled equity generally becomes liquid at a recapitalization. A large share of DSOs anticipate a recap within a one-to-three-year horizon, but anticipation is not a commitment, and the timing is not yours to set.
What are you giving up to hold it? Every dollar of equity is a dollar not taken as cash at close. That is a real trade, and it should be priced deliberately rather than accepted as a package.
I have watched owners sign co-investment deals having asked none of these, on the reasonable-sounding basis that equity in a growing company is obviously good. Sometimes it is.
The point is that you can find out before signing rather than after.
The equity question, worked through
Abstract equity talk is useless. Numbers make it decidable.
Take a practice with $900,000 of adjusted EBITDA. Say the offer values it at 8x, so $7.2 million, structured as 70% cash and 30% rolled equity.
That is $5.04 million at close and $2.16 million of paper.
Now ask what the paper is actually worth.
Scenario one. The organization grows, recapitalizes in four years at a valuation 1.8 times where it stood when you joined. Your $2.16 million becomes roughly $3.9 million.
Total consideration lands near $8.9 million rather than $7.2 million. The equity was the best decision in the deal.
Scenario two. The recap happens at roughly flat. You get your $2.16 million back, four years later, having carried the risk and lost the use of the money.
Not a disaster. Not a win either.
Scenario three. Growth disappoints and preferences rank ahead of you. Common equity underneath a preference stack can return a fraction of its stated value.
Your $2.16 million is worth materially less, and there is nothing you can do about it from where you sit.
Nobody can tell you which scenario you are in. That is the honest position, and any advisor who claims otherwise is guessing.
What you can do is ask where the equity sits, what ranks above it, and when a liquidity event is expected. Then price the offer against a straight cash alternative from a competing buyer.
One more thing the worked example shows. The split is negotiable, not fixed.
Owners tend to read 70/30 as the organization’s policy. Frequently it is an opening position, and owners who wanted more cash have got more cash.
What decides it is whether anyone else is bidding.
Which is the real argument for competition here. Without another bid you cannot even tell whether 70/30 is the right split, because you have nothing to compare it against.
What changes day to day
MB2’s positioning centres on doctors retaining ownership and clinical direction while administrative and operational support is handled centrally. The local practice brand generally survives rather than converting to a house banner.
As with any buyer, the reliable way to test what that means is not the pitch. It is a conversation with dentists who affiliated at least two years ago, long enough for integration to have happened and any honeymoon to have ended.
Ask for two. Ask what decisions remained theirs.
Ask what their week looks like now compared with before, and whether the support they were promised actually showed up. A confident organization arranges that call quickly.
Hesitation or a single carefully chosen reference tells you something at no cost.
The terms genuinely worth pinning down in writing, at any buyer: which clinical decisions stay with you, your post-sale role and hours, what happens to your team’s roles and pay, whether your practice name survives, and who your day-to-day contact is.
What an offer typically contains
MB2 does not publish a price sheet, and neither does any other organization in this market. What a buyer pays depends on the practice, the geography, their current appetite, their capital position, and above all on who else is bidding. Any source quoting you a specific multiple for a named buyer is generalizing from limited data.
What holds broadly across the PE-backed pool, rather than for any one organization:
Cash at close is typically a portion of the headline figure, not all of it. Rollover equity makes up part of the balance, and in a partnership model it is a larger part by design. Earnout may make up the rest, paid only if agreed targets are met after closing.
Two offers with identical headline numbers can therefore be worth materially different amounts, and a co-investment offer is especially hard to compare against a straight cash offer without doing the work.
How to know whether the offer is competitive
Here is what actually decides your outcome, and it is not which organization you are talking to.
A buyer who approaches you directly is competing with nobody. Their offer reflects that, and it would be strange if it did not.
The same organization, bidding against three others who also want your practice, behaves differently — not because the first number was dishonest, but because the leverage changed.
The pool is deep enough for that to be real. Becker’s Dental Review tracked more than 200 DSO affiliations in 2025, and 69 percent of DSOs reported in 2026 that their sponsors expect increased acquisition activity.
Roughly 30 to 35 organizations acquire independent general practices at meaningful scale.
And regional platforms frequently outbid national ones inside their own footprint. Filling a gap in a market they already run delivers density and shared-cost benefits.
A scattered national addition delivers none of that.
Creating that competition is what the Elite Selling System exists to do.
We hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, then run a private competitive window inside that group.
With a co-investment offer this matters even more than usual, because competition is what lets you negotiate the proportions — how much cash, how much equity, where that equity sits — rather than accepting the structure as presented.
One last thing about co-investment offers specifically.
The structure is easier to accept than to unwind. Once you have signed, the proportions are fixed for years.
Ask the hard questions while the answer can still change something.
What to do next
If an MB2 approach is in front of you, the first task is not to compare it against your expectations. It is to convert it into terms you can actually compare.
Get your adjusted EBITDA documented, which is what the practice earns after paying a market-rate dentist to do the work you currently do yourself.
Separate the cash at close from the equity and the earnout, and value the equity honestly rather than at its stated number. Then find out what the practice attracts when several qualified organizations are competing for it.
The partnership model may well suit you. For an owner who wants liquidity without leaving, who likes the idea of a second payout, and who is comfortable holding an illiquid position for several years, it can be a genuinely better fit than a clean sale.
Plenty of dentists have found exactly that.
The point is to choose it on the numbers rather than on the framing.
We will give you that assessment free and in confidence, including the answer that you should wait and fix a few things first when that is the honest one. It starts with a free, confidential practice value estimate.
Our fee varies depending on the value of the practice and is entirely success-based. If we do not get you a result, we do not get paid.
Frequently asked questions
Does MB2 Dental buy dental practices?
Yes, and it is among the most active buyers in the market. In January 2026 alone MB2 partnered with 11 practices across five states and welcomed seven new doctor partners.
What is a DPO, and how is it different from a DSO?
A dental partnership organization keeps the affiliating dentist as a meaningful owner through co-investment, and usually preserves the local practice name. A conventional DSO structure more often involves a fuller exit and, in some cases, conversion to a house brand.
Who owns MB2 Dental?
MB2 is backed by Warburg Pincus and Charlesbank Capital Partners. It was founded in 2007 and supports roughly 800 offices with affiliated practices across more than 45 states.
Is rollover equity in a partnership model a good deal?
It can be genuinely valuable or largely illusory, depending on where the equity sits, what liquidation preferences rank above it, and when a liquidity event is realistically expected. Those three questions should be answered before signing, not after.
What does MB2 Dental pay for a practice?
There is no published price sheet, and any specific multiple attached to a named buyer is generalized from limited data. What any organization pays depends on the practice, the market, their appetite and who else is bidding.
Will I keep my practice name and clinical control?
The partnership model is positioned around retained ownership and clinical direction, with local branding generally preserved. Treat that as the starting point and get the specific decisions that remain yours written into the agreement.
Are the biggest DSOs the most likely buyers for my practice?
Usually not. The 200-to-500-office mid-market platforms complete the most affiliations per platform, and of the three largest DSOs only Heartland Dental is substantially acquisition-led.
Should I accept a direct offer from MB2?
Not before other qualified buyers have bid. This matters more with a co-investment offer than a cash one, because competition is what lets you negotiate the mix of cash and equity rather than accepting the structure as presented.
Sources
MB2 Dental scale, ownership and activity
- Charlesbank Capital Partners. “MB2 Dental.” charlesbank.com
- PitchBook. “MB2 Dental Company Profile: Valuation, Funding & Investors.” pitchbook.com
- Group Dentistry Now. “DSO Deal Roundup — January 2026.” groupdentistrynow.com
- Group Dentistry Now. “DSO Deal Roundup — July 2026.” groupdentistrynow.com
- Becker’s Dental Review. “52 DSOs to know: 2026.” beckersdental.com
- Becker’s Dental Review. “The largest DSOs headed into 2026.” beckersdental.com
Buyer pool, deal activity and market structure
- Association of Dental Support Organizations. “About ADSO.” theadso.org
- Becker’s Dental Review. “200+ DSO affiliations in 2025: State-by-state breakdown.” beckersdental.com
- Becker’s Dental Review. “69% of DSOs plan to boost acquisitions in 2026: Report.” beckersdental.com
- Becker’s Dental Review. “The big trends driving DSO growth in 2026.” beckersdental.com
- Becker’s Dental Review. “What the 3 largest DSOs have been up to.” beckersdental.com
- Becker’s Dental Review. “Dentistry’s biggest players.” beckersdental.com
Deal structure, process and regulation
- Mandelbaum Barrett PC. “The Four-Phase DSO Transaction Process.” mblawfirm.com
- Cranfill Sumner LLP. “Selling Your Dental Practice to a DSO.” cshlaw.com
- Benesch. “Dental/DSO Industry Newsletter, May/June 2026.” beneschlaw.com
- Congressional Research Service. “Private Equity Investments in Health Care: Selected Enforcement Issues.” congress.gov
- US House Committee on Oversight. “Survey of State Laws Governing the Corporate Practice of Dentistry.” oversight.house.gov
Ownership trends and practice economics
- ADA Health Policy Institute. “Practice Ownership Trends in Dentistry.” ada.org
- ADA News. “More dentists affiliating with DSOs.” adanews.ada.org
- ADA Health Policy Institute. “The State of the U.S. Dental Economy, Q1 2026 Update.” ada.org
- ADA Health Policy Institute. “Dental Practice Research.” ada.org
Melani Seymour, co-founder of Transitions Elite, helps veterinary practice owners take action now to maximize value and secure their future.
With over 15 years of experience guiding thousands of owners, she knows exactly what it takes to achieve the best outcome.
